Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 09 - 27 symbols : LLY save search
New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary
Published: 2021-09-27 (Crawled : 13:15) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
AnHeart and Innovent Announce Interim Data from Phase Ⅱ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
Published: 2021-09-27 (Crawled : 13:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
heart positive trial
Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002
Published: 2021-09-27 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
antibody clearance
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
Published: 2021-09-27 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.89%
H: 0.54%
C: 0.51%
phase 2 heart positive trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.